\
&
Contact us
\
&
Contact us
Starts in 1 week from now
LocationBerlin, Germany
ProgrammesThe first EP PerMed Conference on 11 and 12 February will provide an international forum for up to 400 participants to present and discuss research and methodologies in various fields supporting the development of personalised medicine approaches. The event is an opportunity for experts in the field to create new connections and research networks.
Back-to-back with the conference, EP PerMed is organising a training workshop on “Training on Scientific Integrity” on 12 and 13 February. The number of participants to the training workshop is limited. Register on the event's webpage.
More information on the conference and registration on the EP PerMed website.
Background: The European Partnership for Personalised Medicine (EP PerMed) brings together European as well as international, national and regional ministries and funding organisations, agencies and authorities, joining forces on several levels and sectors. To realise the full potential of personalised medicine (PM), EP PerMed supports the entire PM value continuum by a wide range of definite actions, including joint research funding and supporting activities among others.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Health Digital, Industry & Space Climate, Energy, Mobility AI, data & cloud Deployment: Best use of technologies
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
